anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To describe the unique finding and treatment of a dog with cardiac herniation due to traumatic pericardial rupture.
CASE SUMMARY: A 6.5-year-old entire male Yorkshire Terrier was presented for further management after being hit by a car. Despite suspected significant intrathoracic trauma at that time, the patient regained hemodynamic stability and had orthopedic surgery to correct a right iliac fracture. The patient was readmitted to the hospital 12 days following the initial visit due to considerable respiratory difficulty after accidentally being dropped several feet. Thoracic radiographs revealed an unusual severe mediastinal shift to the left with an atypical position of the cardiac silhouette against the left lateral thoracic wall. Due to the severe respiratory compromise of the patient and newly developed pneumothorax, an exploratory thoracotomy was recommended, where a complete rupture of the pericardium was identified, with secondary left-sided prolapse of the heart. Other more common intrathoracic injuries (ie, lung perforation, rib fractures) were also identified and partially repaired. The patient recovered successfully and was discharged 4 days postoperatively.
NEW OR UNIQUE INFORMATION PROVIDED: This is the first case report in the veterinary literature of traumatic pericardial rupture and cardiac herniation. According to human case descriptions, this is a rare and often fatal occurrence, which can be significantly challenging to diagnose preoperatively or antemortem. Emergency veterinary clinicians should be aware of this rare but important complication of blunt thoracic trauma. Surgical intervention may be necessary in cases with suspected or confirmed entrapment of great vessels or cardiac chambers, although these abnormalities were not present in this case.
###  Risk Summary

There are no available data on the presence of fluticasone propionate in human milk, the effects on the breastfed child, or the effects on milk production. Fluticasone propionate is present in rat milk (see Data). Other corticosteroids have been detected in human milk. However, fluticasone propionate concentrations in plasma after orally inhaled therapeutic doses are low, and therefore, concentrations in human breast milk are likely to be correspondingly low [see Clinical Pharmacology (12.3)]. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for XHANCE and any potential adverse effects on the breastfed child from XHANCE or from the underlying maternal condition.

###  Data

Subcutaneous administration of tritiated fluticasone propionate at a dose in lactating rats approximately 0.1 times the MRHDID for adults (on a mcg/m2 basis) resulted in measurable levels in milk.
Biliary tract cancers encompass a group of malignancies that affect the bile ducts and gallbladder and are associated with a poor prognosis, often due to late diagnosis and limited treatment options. The incidence of biliary tract cancer has been increasing gradually, underscoring the need for a better understanding of its pathogenesis and potential risk factors. Research suggests that biliary tract cancer may develop through a combination of genetic and epigenetic alterations, as well as environmental factors. The role of microbial exposure and the human microbiome in the pathogenesis of biliary tract cancer is an emerging area of interest. Traditionally, the biliary tree was considered sterile under normal conditions, but recent studies have identified associations between specific microbiological patterns and inflammatory biliary diseases and cancer. The human microbiome plays a crucial role in maintaining host homeostasis and interacting with the host's immune system. Dysbiosis, or an imbalance in the microbiome composition, has been implicated in the development of various diseases, including cancer. Hence, dysbiosis in the biliary tract might trigger the pathogenesis of biliary tract cancer. Advances in next-generation sequencing technology have provided researchers with a more comprehensive view of the microbiota and their potential roles in health and disease, providing more evidence of the relationship between the microbiota and biliary tract cancer. This review summarizes the latest evidence of the microbiome that would be associated with biliary tract cancer.
Chest disease refers to a wide range of conditions affecting the lungs, such as COVID-19, lung cancer (LC), consolidation lung (COL), and many more. When diagnosing chest disorders medical professionals may be thrown off by the overlapping symptoms (such as fever, cough, sore throat, etc.). Additionally, researchers and medical professionals make use of chest X-rays (CXR), cough sounds, and computed tomography (CT) scans to diagnose chest disorders. The present study aims to classify the nine different conditions of chest disorders, including COVID-19, LC, COL, atelectasis (ATE), tuberculosis (TB), pneumothorax (PNEUTH), edema (EDE), pneumonia (PNEU). Thus, we suggested four novel convolutional neural network (CNN) models that train distinct image-level representations for nine different chest disease classifications by extracting features from images. Furthermore, the proposed CNN employed several new approaches such as a max-pooling layer, batch normalization layers (BANL), dropout, rank-based average pooling (RBAP), and multiple-way data generation (MWDG). The scalogram method is utilized to transform the sounds of coughing into a visual representation. Before beginning to train the model that has been developed, the SMOTE approach is used to calibrate the CXR and CT scans as well as the cough sound images (CSI) of nine different chest disorders. The CXR, CT scan, and CSI used for training and evaluating the proposed model come from 24 publicly available benchmark chest illness datasets. The classification performance of the proposed model is compared with that of seven baseline models, namely Vgg-19, ResNet-101, ResNet-50, DenseNet-121, EfficientNetB0, DenseNet-201, and Inception-V3, in addition to state-of-the-art (SOTA) classifiers. The effectiveness of the proposed model is further demonstrated by the results of the ablation experiments. The proposed model was successful in achieving an accuracy of 99.01%, making it superior to both the baseline models and the SOTA classifiers. As a result, the proposed approach is capable of offering significant support to radiologists and other medical professionals.
The invention comprises D-nor-steroids and a process for the production thereof by dissolving a steroid substituted in the D-ring by a keto group and by a diazo group in a position a - to the keto group, in an inert solvent containing a compound which can be added across the double bond of a ketene, photolysing the solution and isolating the D-nor-steroid thus produced.  By employing a 16-diazo-17-keto androstane or estrane dissolved in an inert solvent containing water, ammonia, an alcohol or primary or sec. amine, there is produced a D-nor-16b -carboxylic acid, carboxylic amide, carboxylic acid ester or -N-mono- or disubstituted-carboxylic acid amide.  Further transformations may be effected, e.g. by converting the D-nor-16b -carboxylic acid to the corresponding acid chloride, followed by reaction with an organo-metallic compound or with diazomethane to form a D-nor-pregnane derivative, degrading the D-nor-pregnane derivative to obtain a D-nor-androstane derivative which on pyrolysis gives a D-nor-estrane derivative.  The starting a -diazo-keto steroid may be obtained by reacting the corresponding a -oximino-keto steroid with chloramine.  Pharmaceutical compositions containing the above compounds and having estrogenic, androgenic, anti-inflammatory, cortical, cholesterol-lowering, anabolic, progestational and antifertility activity are administered orally or parenterally.
Patients receive yttrium Y 90 glass microspheres IA. Approximately 4 weeks after yttrium Y 90 glass microspheres treatment, patients receive nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The educational package included the offering of the Self-Esteem , Associative strengths, Resourcefulness, Action-planning and Responsibility (SARAR) Participatory Hygiene and Sanitation Transformation (PHAST) approach, a 52 minutes educational movie and accompanying cartoon booklet. The package was developed using the PRECEDE approach.
Kidney damage is a serious prevalent complication that occurs after a myocardial infarction (MI) and is associated with worse outcomes. Interleukin-33 (IL-33), a member of the IL-1 superfamily, functions as an alarmin that is released upon necrosis or tissue damage to alert immune cells expressing the ST2L receptor. IL-33 is increased in kidney disease, and recent studies have shown that the IL-33/ST2 axis is instrumental in both disease progression and repair. In this study, we investigated the effect of IL-33 administration on kidneys in C57BL6/J male mice 4 and 7 days after the induction of MI. The mice received either IL-33 or vehicle (PBS) treatment. Cardiac systolic function and systemic inflammation were assessed, and kidneys were subjected to histological and molecular analysis. The administration of IL-33 for 4 days post-MI improved renal structure consistent with reduced expression of profibrotic markers, reduced apoptosis, and increased expression of the anti-inflammatory cytokine IL-4. In addition, IL-33 administration enhanced the levels of Sirtuin3, nicotinamide phosphoribosyltransferase, and the renal nicotinamide adenine dinucleotide pool which are critical for mitochondrial function and energy production, indicating metabolic benefits. However, this protection seems to be lost with the continued administration of IL-33 for 7 days post-MI coinciding with aggravated cardiac dysfunction and increased systemic inflammation. These findings demonstrate that while IL-33 treatment can help improve kidney damage post-MI in the short term, extended treatment may not be beneficial. This may be due to the direct effects of IL-33 on the kidneys or indirectly mediated by adverse cardiac remodeling influencing the cardiorenal crosstalk.
Synthetic multiepitopic chimera as a vaccine and treatment against leishmaniasis in mammals. The invention relates to synthetic chimeras including 4 multiepitopic peptides against Leishmania. Each of the peptides has been selected from a Leishmania infantum protein. These are the nucleosomal histones H2A, H2B, H3 and H4. The invention also relates to a pharmaceutical composition that includes one of these synthetic chimeras. It also refers to a prophylactic and/or therapeutic vaccine against Leishmania spp for use in mammals and especially in humans and dogs. (Machine-translation by Google Translate, not legally binding)
The immune system and inflammatory processes play crucial roles in the development of esophageal cancer (EC). This study aimed to investigate the causal relationships between 731 immune cell phenotypes, 91 circulating inflammatory proteins, and EC, with a particular focus on the mediating role of circulating inflammatory proteins. Utilizing public genetic data, we applied a 2-sample Mendelian Randomization (MR) method to examine the causal relationships between 731 immune cell phenotypes, 91 circulating inflammatory proteins, and EC. Comprehensive sensitivity analyses were conducted to assess the robustness, heterogeneity, and horizontal pleiotropy of the MR results. Additionally, a 2-step MR method was employed to quantify the impact and proportion of immune cell phenotypes mediated by circulating inflammatory proteins on EC. Eleven immune cell phenotypes and 1 inflammatory cytokine were found to have causal relationships with EC, with results stable across all sensitivity analyses. Mediation analyses revealed that only 2 cell phenotypes had causal relationships with EC through interleukin-10: CD3 on human leukocyte antigen-DR (HLA-DR)+ T cells (mediation effect = -0.009; mediation proportion = 12.01%) and monocytic myeloid-derived suppressor cell absolute count (mediation effect = 0.018; mediation proportion = 18.97%). This study enhances the understanding of the causal relationships between immune cells, circulating inflammatory proteins, and EC. The findings highlight the potential mediating role of interleukin-10, providing new insights into the mechanisms by which immune cells may influence esophageal tumorigenesis.
Glutathione (GSH) depletion, mitochondrial damage, and oxidative stress have been implicated in the pathogenesis of acetaminophen (APAP) hepatotoxicity. Here, we demonstrated that the expression of histone deacetylase 6 (HDAC6) is highly elevated, whereas malate dehydrogenase 1 (MDH1) is downregulated in liver tissues and AML-12 cells induced by APAP. The therapeutic benefits of LT-630, a novel HDAC6 inhibitor on APAP-induced liver injury, were also substantiated. On this basis, we demonstrated that LT-630 improved the protein expression and acetylation level of MDH1. Furthermore, after overexpression of MDH1, an upregulated NADPH/NADP+ ratio and GSH level and decreased cell apoptosis were observed in APAP-stimulated AML-12 cells. Importantly, MDH1 siRNA clearly reversed the protection of LT-630 on APAP-stimulated AML-12 cells. In conclusion, LT-630 could ameliorate liver injury by modulating MDH1-mediated oxidative stress induced by APAP.
BACKGROUND: Integrating outcome information into the process of shared decision-making (SDM) about post-treatment surveillance can enhance its effectiveness. The Breast Cancer Surveillance Decision Aid (BCS-PtDA) integrates risk estimations of patients' risks for recurrences as well as outcome information on fear of cancer recurrence (FCR). The SHOUT-BC study aimed to evaluate the effectiveness of the implementation of the BCS-PtDA. Patients' satisfaction with the BCS-PtDA was also evaluated.
METHODS: As described in a previously published protocol paper, the study employed a Prospective multiple interrupted time series (ITS) design in which the BCS-PtDA was implemented stepwise into the care pathways of eight Dutch hospitals.
RESULTS: A total of 507 participants completed a questionnaire after their first surveillance consultation which usually takes place approximately one year after surgery. ITS analysis per hospital and subsequent meta-analysis over hospital effects indicated a significant increase in patient-reported SDM from pre- to post-implementation (overall estimated effect: 27.14, 95 % CI: 22.71 to 31.87, p < .0001). Moreover, post-implementation participants (n = 225) reported a more active role in decision-making, decreased decisional conflict, and increased knowledge on the aim and methods of surveillance. Furthermore, a decrease in FCR was seen post-implementation. The self-reported intensity of surveillance schedules decreased slightly and the BCS-PtDA received highly positive evaluations.
DISCUSSION: The implementation of the BCS-PtDA, which integrates outcome information, led to increased patient-reported SDM and an improved quality of decision-making. The BCS-PtDA was evaluated highly positively by participants. Further research should address optimisation of the implementation.
A purposeful sample of 10 kidney transplant patients will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
A producing method is disclosed for liposome sensitive to PH and for targeting stem cells and cancer cells simultaneously. A compound was mixed from the group of phosphatidylethanolamine -beta-oleyl -gamma- palmitoyle (POPE), dipalmitoyle phosphatidyl acid (DPPA), and cholesterol hemisuccinate (CHOH); followed by adding lipid containing 8-10% mole of the galactose group. The FTV liposome was best in capture rate and stability and showed more leakage depending on pH at 37degree C (Fig.1). As the pH sensitivity increases with galacto cerebroside and CHOH, the leakage was large in the environments like cancer cells. The pH sensitivity was excellent with the compounds of POPE/DPPA, POPE/CHOH, or DOPE/CHOH. The measurement of the amount of ANTS/DPX leaking from liposome at 4degree C and 37degree C indicated the ability of long storage at 4degree C (Fig.2A), very fast leakage at 37degree C, and varying leakage speed depending on the composition (Fig.2B). The stability of liposome with plasma was best with DPG and CHOH (Fig.3). Within the plasma, stability was best with liposomes using POPE/CHOH or POPE/DPG constitution. Two hours after injecting in the tail vein of a rat, the liposome remained more than 70% in stem cells, about 10% in plasma, and about 15% in kidney (Fig.4). Therefore the liposome containing the compositions sensitive to pH and being added with 8-10% mole galacto cerebroside may target the stem cells.
This study will enrol 30 subjects at 3 sites in China. Subjects who fulfil all the inclusion criteria and none of the exclusion criteria will be enrolled and receive treatment with Durvalumab and EP for 4 cycles. Durvalumab will be administered at a dose of 1500 mg every 3 weeks (Q3W) with first-line chemotherapy and will continue to be administered as monotherapy every 4 weeks(Q4W) post-chemotherapy until progressive disease. The LDRT deals with primary tumour in a 15 Gy of 5 fractions over five days, starting from Day 1 in the first cycle. Subjects will attend safety follow up 12 weeks ±14 days after last dose of Durvalumab. The primary endpoint is mPFS.
Tablet providing zero-order of medicament has a core and enveloping sustained-release layer(s) comprising medicament (I), hydrophobic gel and excipients. The concn. of (I) in the core and each layer is a constant and the amt. (DL) of (I) in the core or any given layer is given by the relationship, DL=DTx(RD/RT). Where (DT is the total amt. of (I) in the sustained-release portion of the tablet; RD is the differential radius for the core or given enveloping layer; and RT is the radius of the sustained release portion). Pref. (I) include terbutaline, terfenadine and pseudoephedine hydrochloride.
The environment has long been considered a crucial factor influencing the onset and progression of pulmonary diseases. Environmental therapy is also a practical treatment approach for many conditions. While research has explored the effects of factors like air pressure and oxygen concentration on pulmonary arterial hypertension (PAH), the impact of air humidity on PAH has not been investigated. In this study, we examined the role of different air humidity levels in a mouse model of PAH by controlling relative humidity. We induced PAH in mice using 10 % hypoxia, which led to significant thickening of the pulmonary vasculature, elevated right ventricular systolic pressure, and an increased right ventricular hypertrophy index (RVHI). However, when exposed to an environment with 80-95 % relative humidity, there was a marked reduction in the extent of pulmonary vascular remodeling, decreased vascular thickening, and lower RVHI, effectively preserving right heart function. Notably, changes in the Bmpr2/Tgf-β signaling pathway were significant and may play a pivotal role in this protective effect. In summary, our findings indicate that high relative humidity confers a protective effect on hypoxia-induced PAH in mice, providing novel insights into potential treatments for PAH.
Stroke is the third leading cause of death in the United States and other developed countries and a major source of disability. Prognosis for regaining the ability to walk is good, with 64% of those initially dependent in walking regaining independence by 3 months. However, many gait abnormalities persist. A conservative estimate suggests that 20% of stroke survivors have a drop foot. Drop foot following stroke is caused by paresis of the ankle dorsiflexor muscles. It prevents the patient from effectively swinging the leg during walking, causing an abnormal gait characterized by hip hitching and circumduction and toe catch. Walking speed in people with drop foot is often significantly reduced and the risk of stumbling or falling is high. The conventional treatment for drop foot is an ankle-foot orthosis (AFO). While AFOs are appropriate for many patients, in certain patient groups AFOs have significant limitations (e.g. in patients with strong spasticity, suffering from pronounced inversion, suffering from volume changes in the lower extremity, etc). An alternative way of treating drop foot is by means of functional electrical stimulation. Clinical studies evaluating the effectiveness of drop foot stimulation suggest that it provides many benefits to patients, such as an improved confidence in walking, increased walking speed and endurance, less effort during walking and reduced spasticity. Implantable systems such as ActiGait are considered therapeutic alternatives specifically for those patients for whom conventional treatments have failed. ActiGait system consists of an external module (antenna and control module), a foot switch transmitting to the external module and an implanted assembly (receiver, pulse train generator, electrodes). The objective of this study is to obtain additional evidence on safety of ActiGait implantation procedure and on its efficacy. The study will enrol 5 subjects that will be implanted and followed for 12 weeks. Efficacy outcomes will be assessed at the baseline and during two follow-up visits (week 6 and 12). Subjects will be asked to walk with and without their preferred walking at the baseline and with and without stimulation at follow-up visits.
The participants in the wait-list group will be told that they are on a waiting list during the first 2 weeks to serve as the no-treatment control. Chronobiology-guided lifestyle interventions will be conducted after the posttest is completed.
The invention provides a nanoparticle scaffold-based nano vaccine, and a preparation method and application thereof, and belongs to the technical field of biology. The invention provides a nanoparticle scaffold protein, the amino acid sequence of which is shown in any one of SEQ ID No. 1-SEQ ID No. 3. The invention uses dioxytetrahydropteridine synthase (LS) polymer protein as a protein bracket, optimizes and reforms LS by using a SpyCatcher-SpyTag/snoopche-SnoopTag orthogonal system, and develops a SpyCatcher-LS-SnoopTag nano vaccine universal platform. The nanoparticle scaffold protein can be applied to the research and development of duplex vaccines, and provides a brand-new idea for the research and development of multivalent vaccines of other diseases.
Background: Shrinkage of the free gingival graft (FGG) and patient's discomfort during healing period are important concerns. Therefore, this study aimed to evaluate the effect of low level laser therapy (LLLT) in terms of enhancing wound healing, reducing graft shrinkage and postoperative pain.

Methods: Thirty patients were randomly assigned to receive either FGG+ LLLT (test, n = 15) or FGG + placebo LLLT (control, n = 15). In the test group, a diode laser (aluminum-gallium-arsenide, 810 nm, 0.1 W, continuous mode, time of irradiation:60 s, energy density: 6 J/cm2, spot size:0.5 cm) was applied immediately after the FGG surgery and 1,3,7, and 14 days later. The control group received the same sequence of irradiation with the laser-off. Comparison of the graft surface areas between groups at 1st, 3rd and 6th months were made with an image-analyzing software. Complete wound epithelization, visual analogue scale (VAS) pain score of recipient site and the number of analgesic used were evaluated after the surgery.